Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-978 in Treatment-Refractory Rheumatoid Arthritis
NCT06994143Phase 1Recruiting
- Sponsor
- Cullinan Therapeutics
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of CLN-978 in rheumatoid arthritis (RA) (2 arms), sponsored by Cullinan Therapeutics. Primary endpoint: Incidence and severity of adverse events at 48 weeks. Started May 2025; status: recruiting.
02
Drugs
CLN-978
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06994143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994143.